A Study Of Galcanezumab In Participants With Episodic Cluster Headache

I5Q-MC-CGAL -

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as LY2951742 in participants with episodic cluster headaches.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Episodic Cluster Headache
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
109
Trial Dates
May 22, 2015 - Jun 4, 2018
How long will I be in the trial?
Your participation will include scheduled office visits throughout the study period.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.